Wolf kauft nicht 2 Millionen Aktien, sondern er hat sich eine Option zum Kauf einräumen lassen. Ob und wann er diese zieht, ist ungewiss. Von daher hat das nur bedingte Aussagekraft. Jedenfalls würde ich eine solche "News" nicht traden.
Heat Biologic's COVID-19 Vaccine Demonstrates Robust T Cell Driven Immune Response to SARS-CoV-2 in Preclinical Studies
T cell driven immune response achieved with just a single dose
Potential to be used in combination with other COVID-19 vaccine approaches
DURHAM, NC / ACCESSWIRE / August 13, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported preclinical data for Heat's gp96-based COVID-19. The data, generated at the University of Miami Miller School of Medicine, shows robust T cell mediated immune response directed against the spike protein of SARS-CoV-2.
Heat Biologics' COVID-19 vaccine induced the expansion of both "killer" CD8+ T cells that destroy virus infected cells, as well as "helper" CD4+ T cells that assist in producing highly specific antibodies. Both T cell subsets were shown to release cytokines that amplify the anti-viral immune response and, upon vaccination, memory CD8+ T cells migrated to the lungs and airways-the tissue-specific site of interest for SARS-CoV-2 infection. These lung and airway tissue resident memory CD8+ T cells are crucial in mounting an effective response to respiratory viruses.
Natasa Strbo, MD, DSc, Assistant Professor of Microbiology and Immunology at the University of Miami Miller School of Medicine and co-developer of Heat's gp96 platform, commented, "We are highly encouraged by the animal data generated around the COVID-19 vaccine and we look forward to publishing the full details of this study in the coming weeks. Specifically, we noted several important immune responses generated by the vaccine against SARS-CoV-2 after a single injection, including SARS-CoV-2 specific CD8+ and CD4+ T cells in the lungs and airways."
Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, "We are encouraged by the progress being made by other companies developing vaccines against COVID-19. However, unlike most of these approaches that drive primarily an antibody response, our COVID-19 vaccine is designed to drive predominantly T cell immunity along with antibody responses and innate immunity. As a result, we believe our vaccine has the potential to be used as either a standalone vaccine, or in combination with these other approaches to enhance efficacy. I appreciate the tremendous support of Dr. Strbo and her team at the University of Miami, as well as the team at Heat who have worked around the clock given the urgency of the pandemic. We look forward to providing further updates as soon as possible."
The System for Award Management (SAM) is an official website of the U.S. government. There is no cost to use SAM. You can use this site for FREE to: -Register to do business with the U.S. government -Update or renew your entity registration -Check status of an entity registration -Search for entity registration and exclusion records
Unter Search records im Feld Quick Search Heat Biologics eintragen und suchen lassen oder diese Nummer hier 828572292 unter DUNS number Search eingeben.
sieht es so aus als wenn es ein einziger Coronapush gewesen ist. Dauert nicht mehr lange und wir sehen den 1USD wieder. Wo bleibt die Finanzierung und ein Partner, nichts in Sicht. Bisher alles nur heiße Luft.